Regencell Bioscience Files Interim Financials
Ticker: RGC · Form: 6-K · Filed: 2024-06-20T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, interim-results
TL;DR
Regencell Bioscience just dropped its Dec 31, 2023 interim financials. Check Exhibit 99.1.
AI Summary
Regencell Bioscience Holdings Limited has filed a Form 6-K on June 20, 2024, to furnish its unaudited condensed consolidated interim financial statements for the six months ended December 31, 2023. These financial statements are attached as Exhibit 99.1 to the filing.
Why It Matters
This filing provides investors with updated financial performance data for Regencell Bioscience, crucial for assessing the company's current financial health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant financial changes.
Key Players & Entities
- Regencell Bioscience Holdings Limited (company) — Filer of the report
- 001-40617 (company) — SEC File Number
- Exhibit 99.1 (document) — Unaudited condensed consolidated interim financial statements
FAQ
What period do the furnished financial statements cover?
The unaudited condensed consolidated interim financial statements furnished cover the six months ended on December 31, 2023.
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to furnish the Company's unaudited condensed consolidated interim balance sheets and statement of operations and comprehensive loss for the six months ended December 31, 2023, pursuant to Nasdaq Rule 5250(c)(2).
Where can investors find the financial statements?
The financial statements are attached as Exhibit 99.1 to this Form 6-K report.
What is the company's principal executive office address?
The company's principal executive office is located at 9/F Chinachem Leighton Plaza 29 Leighton Road Causeway Bay, Hong Kong.
Is Regencell Bioscience required to file Form 20-F or Form 40-F annually?
The registrant indicates it files annual reports under cover of Form 20-F.
Filing Stats: 216 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-06-20 09:13:05
Filing Documents
- ea0208118-6k_regencell.htm (6-K) — 9KB
- ea020811801ex99-1_regencell.htm (EX-99.1) — 63KB
- 0001213900-24-054042.txt ( ) — 74KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 20, 2024 Regencell Bioscience Holdings Limited By: /s/ Yat-Gai Au Name: Yat-Gai Au Title: Chief Executive Officer and Chairman of the Board of Directors 2